210 related articles for article (PubMed ID: 37033267)
1. Metabolic syndrome-related prognostic index: Predicting biochemical recurrence and differentiating between cold and hot tumors in prostate cancer.
Ren C; Wang Q; Wang S; Zhou H; Xu M; Li H; Li Y; Chen X; Liu X
Front Endocrinol (Lausanne); 2023; 14():1148117. PubMed ID: 37033267
[TBL] [Abstract][Full Text] [Related]
2. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
Front Immunol; 2022; 13():916800. PubMed ID: 35860239
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment.
Hu B; Zhang X; Zhu S; Wang C; Deng Z; Wang T; Wu Y
Eur J Med Res; 2024 Jan; 29(1):92. PubMed ID: 38297388
[TBL] [Abstract][Full Text] [Related]
4. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
5. A Metabolism-Related Gene Landscape Predicts Prostate Cancer Recurrence and Treatment Response.
Zhou L; Fan R; Luo Y; Zhang C; Jia D; Wang R; Zeng Y; Ren M; Du K; Pan W; Yang J; Tian F; Gu C
Front Immunol; 2022; 13():837991. PubMed ID: 35359973
[TBL] [Abstract][Full Text] [Related]
6. Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy.
Su Q; Liu Z; Chen C; Gao H; Zhu Y; Wang L; Pan M; Liu J; Yang X; Tian J
Cancer Med; 2021 Sep; 10(18):6492-6502. PubMed ID: 34453418
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
8. Lipid metabolism-related miRNAs with potential diagnostic roles in prostate cancer.
Zhai T; Dou M; Ma Y; Wang H; Liu F; Zhang L; Chong T; Wang Z; Xue L
Lipids Health Dis; 2023 Mar; 22(1):39. PubMed ID: 36915125
[TBL] [Abstract][Full Text] [Related]
9. A novel 13 RNA binding proteins (RBPs) signature could predict prostate cancer biochemical recurrence.
Xing Q; Liu S; Luan J; Wang Y; Ma L
Pathol Res Pract; 2021 Sep; 225():153587. PubMed ID: 34419719
[TBL] [Abstract][Full Text] [Related]
10. Necroptosis-Related lncRNAs: Predicting Prognosis and the Distinction between the Cold and Hot Tumors in Gastric Cancer.
Zhao Z; Liu H; Zhou X; Fang D; Ou X; Ye J; Peng J; Xu J
J Oncol; 2021; 2021():6718443. PubMed ID: 34790235
[TBL] [Abstract][Full Text] [Related]
11. T cell proliferation-related genes: Predicting prognosis, identifying the cold and hot tumors, and guiding treatment in clear cell renal cell carcinoma.
Huang H; Cai Y; Hong X; Gao W; Tang J; Zhang S; Xu Z
Front Genet; 2022; 13():948734. PubMed ID: 36118894
[No Abstract] [Full Text] [Related]
12. Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.
Zhao Y; Tao Z; Li L; Zheng J; Chen X
BMC Cancer; 2022 Mar; 22(1):239. PubMed ID: 35246070
[TBL] [Abstract][Full Text] [Related]
13. A Novel Ferroptosis-Based Molecular Signature Associated with Biochemical Recurrence-Free Survival and Tumor Immune Microenvironment of Prostate Cancer.
Ke ZB; You Q; Sun JB; Zhu JM; Li XD; Chen DN; Su L; Zheng QS; Wei Y; Xue XY; Xu N
Front Cell Dev Biol; 2021; 9():774625. PubMed ID: 35071228
[No Abstract] [Full Text] [Related]
14. Single-cell analysis extracted CAFs-related genes to established online app to predict clinical outcome and radiotherapy prognosis of prostate cancer.
Lai C; Wu Z; Li Z; Huang X; Hu Z; Yu H; Yuan Z; Shi J; Hu J; Mulati Y; Liu C; Xu K
Clin Transl Oncol; 2024 May; 26(5):1240-1255. PubMed ID: 38070051
[TBL] [Abstract][Full Text] [Related]
15. Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer.
Wang X; Lv Z; Xia H; Guo X; Wang J; Wang J; Liu M
Cancer Med; 2023 Jan; 12(1):862-878. PubMed ID: 35681277
[TBL] [Abstract][Full Text] [Related]
16. MRI-Derived Radiomics Model to Predict the Biochemical Recurrence of Prostate Cancer Following Seed Brachytherapy.
Zhu X; Liu Z; He J; Li Z; Huang Y; Lu J
Arch Esp Urol; 2023 Jun; 76(4):264-269. PubMed ID: 37455525
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a prognostic risk prediction model incorporating disulfidptosis-related lncRNA for patients with prostate cancer.
Mulati Y; Lai C; Luo J; Hu J; Xu X; Kong D; Xiao Y; Liu C; Xu K
BMC Cancer; 2024 Jan; 24(1):44. PubMed ID: 38191330
[TBL] [Abstract][Full Text] [Related]
18. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer.
Ren L; Yang X; Wang W; Lin H; Huang G; Liu Z; Pan J; Mao X
Front Genet; 2023; 14():1096783. PubMed ID: 36911392
[No Abstract] [Full Text] [Related]
19. A Liquid-Liquid Phase Separation-Related Index Associate with Biochemical Recurrence and Tumor Immune Environment of Prostate Cancer Patients.
You Q; Chen JY; Wu XH; Xue YT; Sun JB; Wei Y; Zheng QS; Xue XY; Chen DN; Xu N
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982591
[TBL] [Abstract][Full Text] [Related]
20. Immune-Related Genes Are Prognostic Markers for Prostate Cancer Recurrence.
Fu M; Wang Q; Wang H; Dai Y; Wang J; Kang W; Cui Z; Jin X
Front Genet; 2021; 12():639642. PubMed ID: 34490029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
